Skip to main content
OpenTrials
Completed

NCT Number: NCT05480215

Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands

Demonstrate safety and effectiveness of symptomatic action tremor relief in the treated hand following stimulation with the Cala Trio System using the Trio+ bands as compared to the Trio bands in adults with Essential Tremor (ET) and/or Parkinson's Disease (PD) over 2 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cala Clinic

San Mateo, California, 94404, United States

About this study

20 patients with (13 with ET and 7 with PD) with at least mild postural tremor were enrolled in a prospective, single-center, two-arm, crossover study that took place over the course of four weeks. TAPS devices were shipped to patients to run the study remotely. In the first arm of the study, subjects received TAPS treatment using the original. Cala Trio band for two weeks. Followed by a wash-out period (> 24 hours), subjects entered the second arm and received TAPS using the Trio+ band for an additional two weeks. Unsupervised motion assessments were captured at home, and at the beginning and end of the four weeks by telemedicine.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be ≥22 years of age
  • Competent and willing to provide written, informed consent to participate in the study
  • Willing to comply with study protocol requirements

For subjects with Essential Tremor:

  • A diagnosis of essential tremor
  • A tremor severity score of 2 or above in the dominant hand/arm as measured by one of the TETRAS upper limb postural tremor items
  • No significant alcohol intake within 8 hours prior to study visits

For subjects with Parkinson's Disease:

  • Dominant hand/arm exhibiting postural tremor ≥ 2 (while in the off state) as assessed by the MDS-UPDRS postural tremor score
  • Stable dose of Parkinson's disease medications, if applicable, for 30 days prior to study entry

Exclusion criteria

  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Any skin condition at the stimulation site that in the investigator's opinion should preclude participation in this study
  • Diagnosed with peripheral neuropathy affecting the tested upper extremity
  • Presence of any other neurodegenerative disease other than essential tremor or Parkinson's Disease
  • Subjects unable to communicate with the investigator and staff
  • Any health condition or concomitant medication that in the investigator's opinion should preclude participation in this study
  • Pregnancy or anticipated pregnancy during the course of the study
  • Botulinum toxin injection for hand tremor within 6 months prior to study enrollment
  • Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor

Treatment and study plan

Cala Device

Device

transcutaneous afferent patterned stimulation (TAPS)

Primary outcomes

  1. Tremor power changes from pre-stimulation to post-stimulation

    Time frame: baseline, pre-intervention and immediately after the intervention

    Tremor improvement was measured by Tremor Power Improvement Ratio (TPIR) using kinematic data collected by the device. The TPIR was calculated as pre-stimulation power divided by post-stimulation power, which was computed from device-collected accelerometer data

Secondary outcomes

  1. Change in TETRAS from pre-stimulation to post- stimulation within each visit

    Time frame: baseline, pre-intervention and immediately after the intervention

    For subjects with Essential Tremor only: Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) subset score, relevant to the stimulated upper limb, change from pre-stimulation to post- stimulation within each visit

  2. Change in UPDRS Part III from pre-stimulation to post- stimulation within each visit

    Time frame: baseline, pre-intervention and immediately after the intervention

    For subjects with Parkinson's Disease only: Modified Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS) subset score, change from pre- stimulation to post-stimulation within each visit

  3. Change in BF-ADL

    Time frame: baseline, pre-intervention and immediately after the intervention

    Change in the Bain & Findley activities of daily living (BF-ADL) score from pre- to post-stimulation at each of the two study visits associated with the Trio and Trio+ bands (four study visits total)

Sponsors and collaborators

Lead sponsor

Cala Health, Inc.

Industry

Registry information

Official study title

Prospective Study for Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jul 29, 2022
Registry last updated
Jul 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.